Patents by Inventor Stephanie Shaw

Stephanie Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis and use of 2?-substituted-N6-modified nucleosides
    Patent number: 8575331
    Abstract: An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: November 5, 2013
    Assignee: Valeant Pharmaceuticals North America
    Inventors: Haoyun An, Kanda Ramasamy, Stephanie Shaw
  • Pyrrolo [2,3-D] pyrimidines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
    Patent number: 8354532
    Abstract: This application concerns certain 2-phenylamino-6-aryl amino-, 6-aryloxy-, and 6-arylthio-purines, -azapurines and -deazapurines. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: January 15, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Yung-hyo Koh, Stephanie Shaw, Hong Woo Kim, Zhi Hong
  • Substituted thieno [2,3-d] pyrimidines as HIV inhibitors
    Patent number: 8324223
    Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: December 4, 2012
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Zhi Hong, Stephanie Shaw, Yung-hyo Koh
  • Substituted Thienol[2,3-d] pyrimidines as HIV Inhibitors
    Publication number: 20120225894
    Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Applicant: Ardea Biosciences, Inc.
    Inventors: Jean-Luc GIRARDET, Zhi HONG, Stephanie SHAW, Yung-hyo KOH
  • PYRROLO [2,3-D] PYRIMIDINES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR TREATMENT OF HIV
    Publication number: 20120226037
    Abstract: This application concerns certain 2-phenylamino-6-aryl amino-, 6-aryloxy-, and 6-arylthio-purines, -azapurines and -deazapurines. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Applicant: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Stephanie Shaw, Hong Woo Kim, Zhi Hong
  • Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of HIV
    Patent number: 8227601
    Abstract: This application concerns certain 2-phenylamino-6-aryl amino-, 6-aryloxy-, and 6-arylthio-purines, -azapurines and -deazapurines. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: July 24, 2012
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Stephanie Shaw, Hong Woo Kim, Zhi Hong
  • Substituted thieno[3,2-d]pyrimidines as HIV inhibitors
    Patent number: 8211898
    Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: July 3, 2012
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Zhi Hong, Stephanie Shaw, Yung-hyo Koh
  • SYNTHESIS AND USE OF 2'-SUBSTITUTED-N6-MODIFIED NUCLEOSIDES
    Publication number: 20110196144
    Abstract: An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
    Type: Application
    Filed: September 7, 2010
    Publication date: August 11, 2011
    Applicant: Valeant Pharmaceuticals North America
    Inventors: Haoyun An, Kanda Ramasamy, Stephanie Shaw
  • Synthesis and use of 2?-substituted-N-modified nucleosides
    Patent number: 7799908
    Abstract: An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
    Type: Grant
    Filed: January 15, 2004
    Date of Patent: September 21, 2010
    Assignee: Valeant Pharmaceuticals North America
    Inventors: Haoyun An, Kanda Ramasamy, Stephanie Shaw
  • 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS
    Publication number: 20090281124
    Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Application
    Filed: July 16, 2009
    Publication date: November 12, 2009
    Applicant: Ardea Biosciences
    Inventors: Jean-Luc Girardet, Zhi Hong, Stephanie Shaw, Yung-hyo Koh
  • Substituted thieno[3,2-D]pyrimidines as HIV inhibitors
    Patent number: 7595324
    Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: September 29, 2009
    Assignee: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Zhi Hong, Stephanie Shaw, Yung-hyo Koh
  • Diaryl-purines, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitor for treatment of hiv
    Publication number: 20090124802
    Abstract: This application concerns certain 2-phenylamino-6-aryl amino-, 6-aryloxy-, and 6-arylthio-purines, -azapurines and -deazapurines. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Application
    Filed: May 5, 2006
    Publication date: May 14, 2009
    Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Stephanie Shaw, Hong Woo Kim
  • NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
    Publication number: 20080249131
    Abstract: Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
    Type: Application
    Filed: May 2, 2008
    Publication date: October 9, 2008
    Applicant: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Zhijun Zhang, Robert Hamatake, Martha A. De La Rosa, Esmir Gunic, Zhi Hong, Hong Woo Kim, Yung-hyo Koh, Shahul Nilar, Stephanie Shaw, Nanhua Yao
  • 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS
    Publication number: 20080176871
    Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Application
    Filed: November 9, 2007
    Publication date: July 24, 2008
    Applicant: ARDEA BIOSCIENCES, INC.
    Inventors: Jean-Luc Girardet, Zhi Hong, Stephanie Shaw, Yung-hyo Koh
  • 2-Beta-modified-6-substituted adenosine analogs and their use as antiviral agents
    Publication number: 20060183706
    Abstract: Various 2?-beta-methyl-6-substituted adenosine analogs (including 2,6-disubstituted adenosine, 8-aza-6-substituted adenosine, and 2-aza-6-substituted adenosine) are prepared by conventional and combinatorial library approaches. Contemplated compounds are particularly useful as therapeutic agents, and especially as antiviral agents.
    Type: Application
    Filed: October 23, 2002
    Publication date: August 17, 2006
    Inventors: An Haoyun, Yili Ding, Stephanie Shaw, Zhi Hong
  • Non-nucleoside reverse transcriptase inhibitors
    Publication number: 20060135556
    Abstract: Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
    Type: Application
    Filed: August 22, 2003
    Publication date: June 22, 2006
    Inventors: Jean-Luc Girardet, Zhijun Zhang, Robert Hamatake, Martha de la Rosa, Esmir Gunic, Zhi Hong, Hong Kim, Yung-Hyo Koh, Shahul Nilar, Stephanie Shaw, Nanhua Yao
  • Synthesis and use of 2'-substituted-n6-modified nucleosides
    Publication number: 20060135465
    Abstract: An improved method of preparing a sugar modified nucleoside analog includes a protocol in which a hydroxy group of a sugar is selectively deprotected and oxidized prior to nucleophilic modification of the corresponding carbonyl group. The modified sugar is then coupled to a heterocyclic base that is modified with a dual nucleophilic reagent in a further step that provides N6-modified adenosine analogs with high stereoselectivity.
    Type: Application
    Filed: January 15, 2004
    Publication date: June 22, 2006
    Applicant: Valeant Research & Development
    Inventors: Haoyun An, Kanda Ramasamy, Stephanie Shaw